Phase 2 N=39 FOLFOX-A in the Treatment of Metastatic or Advanced Unresectable Gastric, Gastro-Esophageal Junction Adenocarcinoma
Gastro-Esophageal Junction Adenocarcinoma · Gastric Cancer
Primary: Objective Response Rate — 15 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=2 Safety and Tolerability of ISX (Isoxsuprine HCL) in MS Relapses
Multiple Sclerosis
Primary: Incidence of Treatment-Emergent Adverse Events in Subjects by Measuring Measuring Changes in Vital Signs — 0; 0 Adverse Events
Phase 2 N=80 A Study of Durvalumab With or Without Tremelimumab in Endometrial Cancer
Endometrial Cancer · Endometrial Carcinosarcoma · Endometrial Carcinoma
Primary: Treatment Efficacy Determined by Measuring the Overall Response Rate — 5; 4 Participants
Phase 3 N=2,441 Study of MK-4482 for Prevention of Coronavirus Disease 2019 (COVID-19) in Adults (MK-4482-013)
Coronavirus Disease (COVID-19)
Primary: Percentage of Participants Who Had Undetectable SARS-CoV-2 in Baseline Nasopharyngeal (NP) Swabs and Developed COVID-19 (Laboratory-Confirmed SARS-CoV-2 Infection With…
N/A N=16 Evaluating Contact Lens Optics
Myopia
Primary: Visual Performance — 0.23; 0.38 logMAR
Phase 4 N=134 Effect of Cequa™ in Subjects With Dry Eye Disease
Dry Eye Disease
Primary: Mean Change in Baseline in Total Corneal Fluoroscein Staining Score — -3.1 score on a scale — p=<0.0001
N/A N=10 Evaluation of the CapScan Device to Measure the Metabolism of Sulfasalazine
Healthy
Primary: Regional Collection of Metabolites and Gut Microbiota — 10 participants with sulfasalazine detected
Phase 4 N=64 Effectiveness of Orally Dosed Emergency Contraception in Obese Women - UPA
Obesity · Contraception
Primary: Number of Participants With Delay in Follicular Rupture Beyond 5 Days — 46; 43; 12 Participants
Phase 1 N=14 Pharmacokinetic Study of a Novel Lipid Formulation of Cannabidiol Compared to a Standard Formulation
Absorption; Chemicals
Primary: Total Drug Exposure. (Area Under the Curve to Infinity [AUC(Inf)] — 674.9; 134.76 ng*h/ml
Phase 3 N=485 MP0420 for Inpatients With COVID-19 (An ACTIV-3/TICO Treatment Trial)
COVID-19
Primary: Number of Participants With Sustained Recovery — 203; 190 Participants
N/A N=2,138 Online Intervention for ANHPI College Students
Tissue and Organ Procurement
Primary: Donor Status — 748; 715; 1030 Participants — p=0.009
Phase 1 N=52 A Study of Tirzepatide (LY3298176) in Healthy Participants
Healthy
Primary: Pharmacokinetics (PK) Part A: Area Under the Concentration Versus Time Curve [AUC (0-∞)] of Tirzepatide — 113000; 109000 nanograms*hours per milliliter(ng*hr/mL)
N/A N=384 User Performance of the Thunder Plus BGMS
Diabetes Mellitus
Primary: Number of Participants With Accurate BGMS Fingerstick Results — 373 Participants
Phase 2 N=16 A Study of Gamma Tocopherol-enriched Supplement on Lower Airway Responses to Inhaled Wood Smoke in Healthy Adults
Airway Inflammation · Asthma
Primary: Change in Sputum % Polymorphonuclear Neutrophils (PMN) With Wood Smoke Particulate (WSP) Exposure — 18.00; 14.75 percent PMNs — p=0.67
Phase 1 N=15 Study of Talimogene Laherparepvec In Children With Advanced Non CNS Tumors
Advanced Non CNS Tumors
Primary: Percentage of Participants Who Experienced a Dose-limiting Toxicity (DLT) — 0.0; 0.0; 100.0; 100.0 Percent of participants